表紙
市場調查報告書

乾眼症症候群的全球市場:產業趨勢與未來預測

Global Dry Eye Syndrome Market: Industry Trends and Forecast to 2026

出版商 Data Bridge Market Research Private Limited 商品編碼 904456
出版日期 內容資訊 英文 359 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
乾眼症症候群的全球市場:產業趨勢與未來預測 Global Dry Eye Syndrome Market: Industry Trends and Forecast to 2026
出版日期: 2019年07月01日內容資訊: 英文 359 Pages
簡介

本報告提供全球乾眼症症候群的市場相關分析,市場基本結構和促進、阻礙因素,整體市場規模趨勢預測,各類別及各地區詳細趨勢,市場競爭環境,主要企業簡介等調查。

第1章 簡介

第2章 市場區隔

第3章 市場概要

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 課題

第4章 摘要整理

第5章 重要考察

第6章 開發中產品分析

  • 概要
  • 已上市產品
  • 已認證/已經登記的產品
  • 臨床實驗第三階段的候補藥
  • 臨床實驗第二階段的候補藥
  • 臨床實驗第一階段的候補藥
  • 其他

第7章 全球乾眼症症候群市場:各產品種類

  • 概要
  • 眼淚刺激劑
    • PILOCARPINE
    • Cyclosporine
    • LIFITEGRAST
  • 人工淚液
    • 分泌促進物質
    • 其他

第8章 全球乾眼症症候群市場:各劑型

  • 概要
  • 液狀
    • 溶液
    • 乳液
    • 懸浮液
  • 半固態
    • 凝膠
    • 軟膏
  • 其他

第9章 全球乾眼症症候群市場:各類藥物

  • 概要
  • 抗發炎劑
  • 潤滑劑
  • 抗感染疾病劑
  • 抗過敏藥
  • 膽鹼促效劑
  • 其他

第10章 全球乾眼症症候群市場:各產品種類

  • 概要
  • 多劑量
  • 單劑量

第11章 全球乾眼症症候群市場:藥物治療的各類型

  • 概要
  • 處方藥 (RX)
  • 成藥 (OTC)

第12章 全球乾眼症症候群市場:容器的各類型

  • 概要
  • 單劑量小瓶

第13章 全球乾眼症症候群市場:包裝的各類型

  • 概要
  • 13.2 PLASTIC
  • 13.3 GLASS
  • 13.4 ALUMINIUM

第14章 全球乾眼症症候群市場:各類型

  • 概要
  • 學名藥
  • 品牌藥
    • RESTASIS
    • XIIDRA
    • REFRESH
    • SYSTANE
    • TEARS NATURALE
    • IKERVIS
    • DIQUAS
    • 其他

第15章 全球乾眼症症候群市場:各終端用戶

  • 概要
  • 家庭治療
  • 醫院
  • 診療所
  • 其他

第16章 全球乾眼症症候群市場:各流通管道

  • 概要
  • 醫院藥局
  • 零售藥局
  • 線上藥局
  • 其他

第17章 全球乾眼症症候群市場:各地區

  • 概要
  • 北美市場 (美國,加拿大,墨西哥)
  • 歐洲市場 (德國,英國,法國,義大利,西班牙,俄羅斯,荷蘭,瑞士,比利時,土耳其等)
  • 亞太地區市場 (日本,中國,印度,韓國,澳洲,新加坡,泰國,馬來西亞,印尼,菲律賓等)
  • 南美市場 (巴西等)
  • 中東、非洲市場 (南非等)

第18章 企業環境:全球乾眼症症候群市場

  • 各企業市場佔有率分析:全球整體
  • 各企業市場佔有率分析:北美市場
  • 各企業市場佔有率分析:歐洲市場
  • 各企業市場佔有率分析:亞太地區市場

第19章 SWOT分析

  • 市場調查分析

第20章 企業簡介

  • ALLERGAN
    • 企業概要
    • 市場收益額分析
    • 企業佔有率分析
    • 各地區的存在感
    • 產品系列
    • 近幾年的主要趨勢
  • NOVARTIS AG
  • BAUSCH & LOMB INCORPORATED.
  • 參天製藥
  • JOHNSON & JOHNSON SERVICES, INC.
  • AKORN, INCORPORATED
  • ALCON INC
  • ALEMBIC PHARMACEUTICALS LIMITED
  • CARDINAL HEALTH
  • CIPLA INC
  • HORUS PHARMA
  • HUBRX
  • NOVALIQ GMBH
  • PERRIGO COMPANY PLC
  • PRESTIGE CONSUMER HEALTHCARE, INC.
  • ROHTO製藥
  • 千壽製藥
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • VISUFARMA

第21章 參考文獻

第22章 調查問卷

第23章 相關調查

目錄

Global dry eye syndrome market is projected to register a substantial CAGR of 6.8% in the forecast period of 2019 to 2026. The new market report contains data for the historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation

By Product Type (Tear stimulators, Artificial tears, Secretagogue, Others), Dosage Type (Liquid, Semi-solid, Others), Drug Class (Lubricating Agents, Cholinergics, Anti-Inflammatory, Anti-Infectives, Anti-Allergics, Others), Dose( Unit dose, Multi-dose), Medication Type( Prescription (Rx) Drugs, Over The Counter (OTC) Drugs), Container Type (Unit-Dose Vials, Bottles, Tubes), Packaging Type( Plastic, Aluminium, Glass), Type (Brands, Generics), End Users (Home Healthcare, Hospitals, Clinics, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa).

Some of the major factors contributing to the growth of the global dry eye syndrome market:

  • Increasing prevalence of the diseases
  • Changing geographical trends to drive the market
  • Increasing awareness about diagnosis and treatment of the disease
  • Rising geriatric population across the world

Market Players:

The key market players for global dry eye syndrome market are listed below:

  • ALLERGAN
  • Bausch & Lomb Incorporated
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Prestige Consumer Healthcare, Inc.
  • AKORN, INC.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Novaliq GmbH
  • Santen Pharmaceutical Co., Ltd.,
  • Cardinal Health
  • Alembic Pharmaceuticals Limited.
  • Cipla Inc.
  • Perrigo Company plc
  • SENJU PHARMACEUTICAL CO. LTD.
  • Horus Pharma
  • ROHTO Pharmaceutical Co., Ltd.
  • VISUfarma
  • Hubrx

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL DRY EYE SYNDROME MARKET
  • 1.4 CURRENCY AND PRICING
  • 1.5 LIMITATIONS
  • 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GLOBAL DRY EYE SYNDROME MARKET: GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7 DBMR MARKET POSITION GRID
  • 2.8 DBMR VENDOR SHARE ANALYSIS
  • 2.9 MULTIVARIATE MODELING
  • 2.10 PRODUCTS LIFELINE CURVE
  • 2.11 SECONDARY SOURCES
  • 2.12 ASSUMPTIONS

3 MARKET OVERVIEW

  • 3.1 DRIVERS
    • 3.1.1 INCREASING PREVALENCE OF DRY EYE DISEASES
    • 3.1.2 CHANGING GEOGRAPHICAL TRENDS TO DRIVE THE MARKET
    • 3.1.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT OF THE DISEASE
    • 3.1.4 RISING GERIATRIC POPULATION ACROSS THE WORLD
    • 3.1.5 INCREASE IN LASIK SURGERY AND USAGE OF CONTACT LENSES
  • 3.2 RESTRAINTS
    • 3.2.1 STRINGENT REGULATORY PROCESS
    • 3.2.2 UNMET MEDICAL NEEDS
  • 3.3 OPPORTUNITIES
    • 3.3.1 EMERGING MARKET PRESENTS SIGNIFICANT OPPORTUNITIES
    • 3.3.2 DEVELOPMENT OF NOVEL TECHNOLOGIES
  • 3.4 CHALLENGE
    • 3.4.1 INCREASING NUMBER OF PLAYERS

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 PIPELINE ANALYSIS

  • 6.1 OVERVIEW
  • 6.2 MARKETED DRUGS
  • 6.3 APPROVED/FILED DRUGS
  • 6.4 PHASE III TRIAL CANDIDATES
  • 6.5 PHASE II TRIAL CANDIDATES
  • 6.6 PHASE I TRIAL CANDIDATES
  • 6.7 OTHERS

7 GLOBAL DRY EYE SYNDROME MARKET, BY PRODUCT TYPE

  • 7.1 OVERVIEW
  • 7.2 TEAR STIMULATORS
    • 7.2.1 PILOCARPINE
    • 7.2.2 CYCLOSPORINE
    • 7.2.3 LIFITEGRAST
  • 7.3 ARTIFICIAL TEARS
    • 7.3.1 SECRETAGOGUE
    • 7.3.2 OTHERS

8 GLOBAL DRY EYE SYNDROME MARKET, BY DOSAGE TYPE

  • 8.1 OVERVIEW
  • 8.2 LIQUID
    • 8.2.1 SOLUTIONS
    • 8.2.2 EMULSIONS
    • 8.2.3 SUSPENSIONS
  • 8.3 SEMI-SOLID
    • 8.3.1 GEL
    • 8.3.2 OINTMENT
  • 8.4 OTHERS

9 GLOBAL DRY EYE SYNDROME MARKET, BY DRUG CLASS

  • 9.1 OVERVIEW
  • 9.2 ANTI-INFLAMMATORY
  • 9.3 LUBRICATING AGENT
  • 9.4 ANTI-INFECTIVE
  • 9.5 ANTI-ALLERGIC
  • 9.6 CHOLINERGIC
  • 9.7 OTHERS

10 GLOBAL DRY EYE SYNDROME MARKET, BY DOSE

  • 10.1 OVERVIEW
  • 10.2 MULTI DOSE
  • 10.3 UNIT DOSE

11 GLOBAL DRY EYE SYNDROME MARKET, BY MEDICATION TYPE

  • 11.1 OVERVIEW
  • 11.2 PRESCRIPTION (RX) DRUGS
  • 11.3 OVER THE COUNTER (OTC) DRUGS

12 GLOBAL DRY EYE SYNDROME MARKET, BY CONTAINER TYPE

  • 12.1 OVERVIEW
  • 12.2 UNIT DOSE VIALS
  • 12.3 BOTTLES
  • 12.4 TUBES

13 GLOBAL DRY EYE SYNDROME MARKET, BY PACKAGING TYPE

  • 13.1 OVERVIEW
  • 13.2 PLASTIC
  • 13.3 GLASS
  • 13.4 ALUMINIUM

14 GLOBAL DRY EYE SYNDROME MARKET, BY TYPE

  • 14.1 OVERVIEW
  • 14.2 GENERIC DRUG
  • 14.3 BRANDED
    • 14.3.1 RESTASIS
    • 14.3.2 XIIDRA
    • 14.3.3 REFRESH
    • 14.3.4 SYSTANE
    • 14.3.5 TEARS NATURALE
    • 14.3.6 IKERVIS
    • 14.3.7 DIQUAS
    • 14.3.8 OTHERS

15 GLOBAL DRY EYE SYNDROME MARKET, BY END USER

  • 15.1 OVERVIEW
  • 15.2 HOME HEALTHCARE
  • 15.3 HOSPITALS
  • 15.4 CLINICS
  • 15.5 OTHERS

16 GLOBAL DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL

  • 16.1 OVERVIEW
  • 16.2 HOSPITAL PHARMACIES
  • 16.3 RETAIL PHARMACIES
  • 16.4 ONLINE PHARMACIES
  • 16.5 OTHERS

17 GLOBAL DRY EYE SYNDROME MARKET BY GEOGRAPHY

  • 17.1 OVERVIEW
  • 17.2 NORTH AMERICA
    • 17.2.1 U.S.
    • 17.2.2 CANADA
    • 17.2.3 MEXICO
  • 17.3 EUROPE
    • 17.3.1 GERMANY
    • 17.3.2 U.K.
    • 17.3.3 FRANCE
    • 17.3.4 ITALY
    • 17.3.5 SPAIN
    • 17.3.6 RUSSIA
    • 17.3.7 NETHERLANDS
    • 17.3.8 SWITZERLAND
    • 17.3.9 BELGIUM
    • 17.3.10 TURKEY
    • 17.3.11 REST OF EUROPE
  • 17.4 ASIA-PACIFIC
    • 17.4.1 JAPAN
    • 17.4.2 CHINA
    • 17.4.3 INDIA
    • 17.4.4 SOUTH KOREA
    • 17.4.5 AUSTRALIA
    • 17.4.6 SINGAPORE
    • 17.4.7 THAILAND
    • 17.4.8 MALAYSIA
    • 17.4.9 INDONESIA
    • 17.4.10 PHILIPPINES
    • 17.4.11 REST OF APAC
  • 17.5 SOUTH AMERICA
    • 17.5.1 BRAZIL
    • 17.5.2 REST OF SOUTH AMERICA
  • 17.6 MIDDLE EAST AND AFRICA
    • 17.6.1 SOUTH AFRICA
    • 17.6.2 REST OF MIDDLE EAST AND AFRICA

18 GLOBAL DRY EYE SYNDROME MARKET, COMPANY LANDSCAPE

  • 18.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 18.3 COMPANY SHARE ANALYSIS: EUROPE
  • 18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

19 SWOT ANALYSIS

  • 19.1 DATA BRIDGE MARKET RESEARCH ANALYSIS-

20 COMPANY PROFILE

  • 20.1 ALLERGAN
    • 20.1.1 COMPANY SNAPSHOT
    • 20.1.2 REVENUE ANALYSIS
    • 20.1.3 COMPANY SHARE ANALYSIS
    • 20.1.4 GEOGRAPHICAL PRESENCE
    • 20.1.5 PRODUCT PORTFOLIO
    • 20.1.6 RECENT DEVELOPMENTS
  • 20.2 NOVARTIS AG
    • 20.2.1 COMPANY OVERVIEW
    • 20.2.2 REVENUE ANALYSIS
    • 20.2.3 COMPANY SHARE ANALYSIS
    • 20.2.4 GEOGRAPHICAL PRESENCE
    • 20.2.5 PRODUCT PORTFOLIO
    • 20.2.6 RECENT DEVELOPMENT
  • 20.3 BAUSCH & LOMB INCORPORATED.
    • 20.3.1 COMPANY SNAPSHOT
    • 20.3.2 REVENUE ANALYSIS
    • 20.3.3 COMPANY SHARE ANALYSIS
    • 20.3.4 GEOGRAPHICAL PRESENCE
    • 20.3.5 PRODUCT PORTFOLIO
    • 20.3.6 RECENT DEVELOPMENT
  • 20.4 SANTEN PHARMACEUTICAL CO., LTD.
    • 20.4.1 COMPANY OVERVIEW
    • 20.4.2 REVENUE ANALYSIS
    • 20.4.3 COMPANY SHARE ANALYSIS
    • 20.4.4 GEOGRAPHICAL PRESENCE
    • 20.4.5 PRODUCT PORTFOLIO
    • 20.4.6 RECENT DEVELOPMENT
  • 20.5 JOHNSON & JOHNSON SERVICES, INC.
    • 20.5.1 COMPANY SNAPSHOT
    • 20.5.2 REVENUE ANALYSIS
    • 20.5.3 COMPANY SHARE ANALYSIS
    • 20.5.4 GEOGRAPHICAL PRESENCE
    • 20.5.5 PRODUCT PORTFOLIO
    • 20.5.6 RECENT DEVELOPMENTS
  • 20.6 AKORN, INCORPORATED
    • 20.6.1 COMPANY OVERVIEW
    • 20.6.2 REVENUE ANALYSIS
    • 20.6.3 GEOGRAPHICAL PRESENCE
    • 20.6.4 PRODUCT PORTFOLIO
    • 20.6.5 RECENT DEVELOPMENT
  • 20.7 ALCON INC
    • 20.7.1 COMPANY SNAPSHOT
    • 20.7.2 REVENUE ANALYSIS
    • 20.7.3 GEOGRAPHICAL PRESENCE
    • 20.7.4 PRODUCT PORTFOLIO
    • 20.7.5 RECENT DEVELOPMENT
  • 20.8 ALEMBIC PHARMACEUTICALS LIMITED
    • 20.8.1 COMPANY SNAPSHOT
    • 20.8.2 REVENUE ANALYSIS
    • 20.8.3 GEOGRAPHICAL PRESENCE
    • 20.8.4 PRODUCT PORTFOLIO
    • 20.8.5 RECENT DEVELOPMENTS
  • 20.9 CARDINAL HEALTH
    • 20.9.1 COMPANY SNAPSHOT
    • 20.9.2 REVENUE ANALYSIS
    • 20.9.3 GEOGRAPHICAL PRESENCE
    • 20.9.4 PRODUCT PORTFOLIO
    • 20.9.5 RECENT DEVELOPMENTS
  • 20.10 CIPLA INC
    • 20.10.1 COMPANY SNAPSHOT
    • 20.10.2 REVENUE ANALYSIS
    • 20.10.3 GEOGRAPHICAL PRESENCE
    • 20.10.4 PRODUCT PORTFOLIO
    • 20.10.5 RECENT DEVELOPMENTS
  • 20.11 HORUS PHARMA
    • 20.11.1 COMPANY OVERVIEW
    • 20.11.2 GEOGRAPHICAL PRESENCE
    • 20.11.3 PRODUCT PORTFOLIO
    • 20.11.4 RECENT DEVELOPMENT
  • 20.12 HUBRX
    • 20.12.1 COMPANY SNAPSHOT
    • 20.12.2 PRODUCT PORTFOLIO
    • 20.12.3 RECENT DEVELOPMENTS
  • 20.13 NOVALIQ GMBH
    • 20.13.1 COMPANY OVERVIEW
    • 20.13.2 GEOGRAPHICAL PRESENCE
    • 20.13.3 PRODUCT PORTFOLIO
    • 20.13.4 RECENT DEVELOPMENT
  • 20.14 PERRIGO COMPANY PLC
    • 20.14.1 COMPANY SNAPSHOT
    • 20.14.2 REVENUE ANALYSIS
    • 20.14.3 GEOGRAPHICAL PRESENCE
    • 20.14.4 PRODUCT PORTFOLIO
    • 20.14.5 RECENT DEVELOPMENT
  • 20.15 PRESTIGE CONSUMER HEALTHCARE, INC.
    • 20.15.1 COMPANY SNAPSHOT
    • 20.15.2 REVENUE ANALYSIS
    • 20.15.3 PRODUCT PORTFOLIO
    • 20.15.4 RECENT DEVELOPMENTS
  • 20.16 ROHTO PHARMACEUTICAL CO., LTD.
    • 20.16.1 COMPANY SNAPSHOT
    • 20.16.2 REVENUE ANALYSIS
    • 20.16.3 GEOGRAPHICAL PRESENCE
    • 20.16.4 PRODUCT PORTFOLIO
    • 20.16.5 RECENT DEVELOPMENT
  • 20.17 SENJU PHARMACEUTICAL CO. LTD.
    • 20.17.1 COMPANY OVERVIEW
    • 20.17.2 REVENUE ANALYSIS
    • 20.17.3 GEOGRAPHICAL PRESENCE
    • 20.17.4 PRODUCT PORTFOLIO
    • 20.17.5 RECENT DEVELOPMENT
  • 20.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 20.18.1 COMPANY SNAPSHOT
    • 20.18.2 REVENUE ANALYSIS
    • 20.18.3 GEOGRAPHICAL PRESENCE
    • 20.18.4 PRODUCT PORTFOLIO
  • 20.19 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 20.19.1 COMPANY SNAPSHOT
    • 20.19.2 REVENUE ANALYSIS
    • 20.19.3 GEOGRAPHICAL PRESENCE
    • 20.19.4 PRODUCT PORTFOLIO
    • 20.19.5 RECENT DEVELOPMENT
    • 20.19.6 RECENT DEVELOPMENTS
  • 20.20 VISUFARMA
    • 20.20.1 COMPANY OVERVIEW
    • 20.20.2 GEOGRAPHICAL PRESENCE
    • 20.20.3 PRODUCT PORTFOLIO
    • 20.20.4 RECENT DEVELOPMENTS

21 REFERENCES

22 QUESTIONNAIRE

23 RELATED REPORTS

LIST OF FIGURES

  • FIGURE 1 GLOBAL DRY EYE SYNDROME MARKET
  • FIGURE 2 GLOBAL DRY EYE SYNDROME MARKET: DATA VALIDATION MODEL
  • FIGURE 3 GLOBAL DRY EYE SYNDROME MARKET: DROC ANALYSIS
  • FIGURE 4 GLOBAL DRY EYE SYNDROME MARKET: GLOBAL VS REGIONAL
  • FIGURE 5 GLOBAL DRY EYE SYNDROME MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 GLOBAL DRY EYE SYNDROME MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 GLOBAL DRY EYE SYNDROME MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 GLOBAL DRY EYE SYNDROME MARKET: DBMR VENDOR SHARE ANALYSIS
  • FIGURE 9 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF GLOBAL DRY EYE SYNDROME MARKET
  • FIGURE 10 GLOBAL DRY EYE SYNDROME MARKET: SEGMENTATION
  • FIGURE 11 EUROPE IS ANTICIPATED TO DOMINATE THE GLOBAL DRY EYE SYNDROME MARKET AND IS ESTIMATED TO BE INCREASING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2019 TO 2026
  • FIGURE 12 INCREASING PREVALENCE OF DRY EYE DISEASES AND CHANGING GEOGRAPHICAL TRENDS TO DRIVE THE MARKET ARE EXPECTED TO DRIVE THE GLOBAL DRY EYE SYNDROME MARKET IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 13 TEAR STIMULATORE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL DRY EYE SYNDROME MARKET IN 2019 & 2026
  • FIGURE 14 NORTH AMERICA IS THE MAXIMUM GROWING AND MOST PROFITABLE REVENUE POCKETS FOR GLOBAL DRY EYE SYNDROME MARKET IN THE FORECAST PERIOD FROM 2019 TO 2026
  • FIGURE 15 GLOBAL DRY EYE SYNDROME MARKET: BY PRODUCT TYPE, 2018
  • FIGURE 16 GLOBAL DRY EYE SYNDROME MARKET: BY DOSAGE TYPE, 2018
  • FIGURE 17 GLOBAL DRY EYE SYNDROME MARKET: BY DRUG CLASS, 2018
  • FIGURE 18 GLOBAL DRY EYE SYNDROME MARKET: BY DOSE, 2018
  • FIGURE 19 GLOBAL DRY EYE SYNDROME MARKET: BY MEDICATION TYPE, 2018
  • FIGURE 20 GLOBAL DRY EYE SYNDROME MARKET: BY CONTAINER TYPE, 2018
  • FIGURE 21 GLOBAL DRY EYE SYNDROME MARKET: BY PACKAGING TYPE, 2018
  • FIGURE 22 GLOBAL DRY EYE SYNDROME MARKET: BY TYPE, 2018
  • FIGURE 23 GLOBAL DRY EYE SYNDROME MARKET: BY END-USER, 2018
  • FIGURE 24 GLOBAL DRY EYE SYNDROME MARKET: BYDISTRIBUTION CHANNEL, 2018
  • FIGURE 25 GLOBAL DRY EYE SYNDROME MARKET: SNAPSHOT (2018)
  • FIGURE 26 GLOBAL DRY EYE SYNDROME MARKET: BY GEOGRAPHY (2018)
  • FIGURE 27 GLOBAL DRY EYE SYNDROME MARKET: BY GEOGRAPHY (2018 & 2026)
  • FIGURE 28 GLOBAL DRY EYE SYNDROME MARKET, BY GEOGRAPHY (2018 & 2026)
  • FIGURE 29 GLOBAL DRY EYE SYNDROME MARKET, BY TYPE (2018 - 2026)
  • FIGURE 30 NORTH AMERICA DRY EYE SYNDROME MARKET: SNAPSHOT (2018)
  • FIGURE 31 NORTH AMERICA DRY EYE SYNDROME MARKET: BY GEOGRAPHY (2018)
  • FIGURE 32 NORTH AMERICA DRY EYE SYNDROME MARKET:BY COUNTRY (2018 & 2026)
  • FIGURE 33 NORTH AMERICA DRY EYE SYNDROME MARKET: BY COUNTRY (2018-2026)
  • FIGURE 34 NORTH AMERICA DRY EYE SYNDROME MARKET, BY TYPE (2018-2026)
  • FIGURE 35 EUROPE DRY EYE SYNDROME MARKET SNAPSHOT (2018)
  • FIGURE 36 EUROPE DRY EYE SYNDROME MARKET: BY COUNTRY(2018)
  • FIGURE 37 EUROPE DRY EYE SYNDROME MARKET: BY COUNTRY(2019)
  • FIGURE 38 EUROPE DRY EYE SYNDROME MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 39 EUROPE DRY EYE SYNDROME MARKET: BY PRODUCTS & SERVICES (2019 - 2026)
  • FIGURE 40 ASIA-PACIFIC DRY EYE SYNDROME MARKET SNAPSHOT (2018)
  • FIGURE 41 ASIA-PACIFIC DRY EYE SYNDROME MARKET: BY COUNTRY(2018)
  • FIGURE 42 ASIA-PACIFIC DRY EYE SYNDROME MARKET: BY COUNTRY(2019&2026)
  • FIGURE 43 ASIA-PACIFIC DRY EYE SYNDROME MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 44 ASIA-PACIFIC DRY EYE SYNDROME MARKET: BY TYPE (2019 - 2026)
  • FIGURE 45 SOUTH AMERICA DRY EYE SYNDROME MARKET: SNAPSHOT (2018)
  • FIGURE 46 SOUTH AMERICA DRY EYE SYNDROME MARKET: BY GEOGRAPHY (2018)
  • FIGURE 47 SOUTH AMERICA DRY EYE SYNDROME MARKET:BY COUNTRY (2018 & 2026)
  • FIGURE 48 SOUTH AMERICA DRY EYE SYNDROME MARKET: BY COUNTRY (2018-2026)
  • FIGURE 49 SOUTH AMERICA DRY EYE SYNDROME MARKET, BY TYPE (2018-2026)
  • FIGURE 50 MIDDLE EAST AND AFRICA DRY EYE SYNDROME MARKET: SNAPSHOT (2018)
  • FIGURE 51 MIDDLE EAST AND AFRICA DRY EYE SYNDROME MARKET: BY GEOGRAPHY (2018)
  • FIGURE 52 MIDDLE EAST AND AFRICA DRY EYE SYNDROME MARKET:BY COUNTRY (2018 & 2026)
  • FIGURE 53 MIDDLE EAST AND AFRICA DRY EYE SYNDROME MARKET: BY COUNTRY (2018-2026)
  • FIGURE 54 MIDDLE EAST AND AFRICA DRY EYE SYNDROME MARKET, BY TYPE (2018-2026)
  • FIGURE 55 GLOBAL DRY EYE SYNDROME MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 56 NORTH AMERICA DRY EYE SYNDROME MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 57 EUROPE DRY EYE SYNDROME MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 58 ASIA-PACIFIC DRY EYE SYNDROME MARKET: COMPANY SHARE 2018 (%)
Back to Top